Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kintor Pharmaceutical Ltd ( (HK:9939) ) has issued an update.
Kintor Pharmaceutical said its in-house developed topical drug KX-826 1.0% achieved the primary endpoint in the phase III stage of a pivotal clinical trial for male androgenetic alopecia in China, delivering statistically significant and clinically meaningful hair growth with an acceptable safety profile. The company plans to move toward an NDA filing in the PRC, positioning KX-826 as a potential first-in-class therapy that could disrupt the decades-old reliance on minoxidil and finasteride, and enhance its competitive standing amid parallel innovation from global peers targeting the same receptor.
The most recent analyst rating on (HK:9939) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Kintor Pharmaceutical Ltd stock, see the HK:9939 Stock Forecast page.
More about Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Limited is a China-focused biopharmaceutical company specializing in innovative dermatology and endocrine-related therapies. Its pipeline includes in-house developed topical drugs such as KX-826 for androgenetic alopecia, targeting unmet medical needs in hair loss treatment in China and global markets.
Average Trading Volume: 3,379,478
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.04B
Find detailed analytics on 9939 stock on TipRanks’ Stock Analysis page.